PRME
NASDAQPrime Medicine Inc.
Prime Medicine Inc. (PRME) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for PRME, including 1 press release or news item. The most recent was published Nov 9, 2026.
PRME rankings
Financial highlights
Full financials- Revenue, FY2025
- $4.63M
- Revenue growth
- +55.3%
- Net income, FY2025
- -$201.14M
- Net margin
- -4342.4%
- Free cash flow, FY2025
- -$167.09M
- Cash
- $47.45M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks25-50%
2026-05-172026-11-08
Mix690d
- Other4(67%)
- Analyst2(33%)
Activity · 52 weeks5029 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRPrime Medicine to Present at Jefferies Global Healthcare ConferenceCAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Monday, November 16, 2026, at 4:00 p.m. GMT (11:00 a.m. ET) in London, United Kingdom. A live audio webcast of the presentation will be available under "Events & Presentations" in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine websi
- PRPrime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson disease-causing mutation in North America and Europe -- -- PM577 granted Rare Pediatric Disease Designation by the U.S. FDA -- -- Initial clinical data expected in 2027 -- CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the first patient has been dosed in the Company’s global Ph
- PRPrime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 -- CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for PM647, an investigational in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency (AATD). The clearance enables PM647 to proceed to clinical stu
- PRPrime Medicine to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: Wells Fargo 21st Annual Healthcare Conference: Company management will host 1x1 meetings on Thursday, September 10, 2026, in Boston, MA.H.C. Wainwright 28th Annual Global Investment Conference: Fireside chat on Tuesday, September 15, 2026, at 9:30 a.m. ET in New York, NY.Morgan Stanley Global Healthcare Conference: Fireside chat on Wednesday, September 16, 2026, at 10:00 a.m. ET in New York, NY. Live
- ANALYSTChardan Capital Markets resumed coverage on Prime Medicine with a new price targetChardan Capital Markets resumed coverage of Prime Medicine with a rating of Buy and set a new price target of $7.00
- ANALYSTBMO Capital Markets initiated coverage on Prime Medicine with a new price targetBMO Capital Markets initiated coverage of Prime Medicine with a rating of Outperform and set a new price target of $9.00
- SECSEC Form 10-Q filed by Prime Medicine Inc.10-Q - Prime Medicine, Inc. (0001894562) (Filer)
- SECPrime Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Prime Medicine, Inc. (0001894562) (Filer)
- PRPrime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable arbitration resolution with Beam Therapeutics affirms Prime Medicine’s rights to PM647 in Alpha-1 Antitrypsin Deficiency; IND and/or CTA submission expected in 3Q 2026, with initial clinical data in 2027 -- -- FDA grants Regenerative Medicine Advanced Therapy designation to PM359; continued regulatory engagement with the FDA toward a BLA submission for PM359 in 1H 2027 -- -- Cash, cash equivalents, investments, and restricted cash of $108.8 million as of June 30, 2026, providi
- PRPrime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe -- -- Initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for PM577a, an investigational in vivo Prime Editor for
- SECPrime Medicine Inc. filed SEC Form 8-K: Other Events8-K - Prime Medicine, Inc. (0001894562) (Filer)
- PRPrime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics-- Arbitration tribunal declared that PM647 is within Prime Medicine’s "Field", confirming Prime Medicine’s right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to Beam Therapeutics -- -- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in Q3 2026, initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties’
- ANALYSTPrime Medicine upgraded by H.C. Wainwright with a new price targetH.C. Wainwright upgraded Prime Medicine from Neutral to Buy and set a new price target of $8.00
- PRPrime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47phox-deficient CGD -- -- Designation enables early and intensive FDA engagement, and provides eligibility for rolling and priority Biologics License Application review -- -- PM359 now holds RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease Designations -- CAMBRIDGE, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.
- PRPrime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe -- -- Initiation of Phase 1/2 clinical trial expected in second half of 2026; initial clinical data expected in 2027 -- -- Shared LNP delivery platform may enable rapid expansion into additional WD pathogenic variant populations; most advanced follow-on candidate targets the R778L mutation frequently found in East Asian populations -- CAMBRIDGE, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new c
- INSIDERSEC Form 4 filed by Director Schenkein David P4 - Prime Medicine, Inc. (0001894562) (Issuer)
- INSIDERSEC Form 4 filed by Director Marrazzo Jeffrey D4 - Prime Medicine, Inc. (0001894562) (Issuer)
- INSIDERSEC Form 4 filed by Director Nelsen Robert4 - Prime Medicine, Inc. (0001894562) (Issuer)
- INSIDERSEC Form 4 filed by Director Kelly Michael Aaron4 - Prime Medicine, Inc. (0001894562) (Issuer)
- INSIDERSEC Form 4 filed by Director Foster-Cheek Kaye I4 - Prime Medicine, Inc. (0001894562) (Issuer)
- INSIDERSEC Form 4 filed by Director Chung Wendy4 - Prime Medicine, Inc. (0001894562) (Issuer)
- INSIDERSEC Form 4 filed by Director Cahill Thomas4 - Prime Medicine, Inc. (0001894562) (Issuer)
- SECPrime Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Prime Medicine, Inc. (0001894562) (Filer)
- PRPrime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceCAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET in Miami Beach, FL. A live audio webcast of the presentation will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 9
- PRPrime Medicine to Present at Jefferies Global Healthcare ConferenceCAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 12:50 p.m. ET in New York, NY. A live audio webcast of the presentation will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the e
PRME FAQ
10 questionsWhat is the latest news on PRME?
In the last 30 days Quantisnow tracked 1 wire item for PRME: 1 press release or news item. The most recent was published on November 9, 2026.What is PRME revenue?
Prime Medicine Inc. (PRME) reported $4.63M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 55.3% from the year before.Is PRME profitable?
No. Prime Medicine Inc. reported a net loss of $201.14M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does PRME have?
Prime Medicine Inc. reported $47.45M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does PRME stock trade?
Prime Medicine Inc. (PRME) is listed on NASDAQ.What sector and industry is PRME in?
Prime Medicine Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Prime Medicine Inc. go public?
Prime Medicine Inc. (PRME) completed its IPO in 2022.What are analysts saying about PRME?
Across the last 8 analyst actions on Prime Medicine Inc., there was 1 upgrade and 3 downgrades. The most recent action was from Chardan Capital Markets: Buy with a $7.00 price target on 2026-08-25.What companies are similar to PRME?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare PRME side-by-side with any of them on Quantisnow.How can I track PRME on Quantisnow?
Quantisnow aggregates Prime Medicine Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRME to receive live email and push alerts on every new disclosure.